suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19
Status:
Active, not recruiting
Trial end date:
2021-12-20
Target enrollment:
Participant gender:
Summary
The SAVE-MORE is a pivotal, confirmatory, phase III randomized clinical trial (RCT) aiming to
evaluate the efficacy and safety of early start of anakinra guided by suPAR in patients with
LRTI by SARS-CoV-2 in improving the clinical state of COVID-19 over 28 days as measured by
the ordinal scale of the 11-point World Health Organization (WHO) clinical progression scale
(CPS).